Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Atara Biotherapeutics, Inc. (ATRA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress Discussions With FDA Progressing on Potential BLA Submission for Tab-cel®With Meeting Scheduled To Resolve Remaining Topic of Comparability ATA188 Phase 2 EMBOLD Study Primary Analysis and Communication Will Now Occur in Early November To Include the Last Patient Visits From More Than 90 Patients IND Cleared for Atara's First Allogeneic CAR T, ATA3219, in Relapsed/Refractory B-Cell NHL THOUSAND OAKS, Calif.—August 8, 2023—Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2023, ..."
06/09/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/12/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/08/2023 8-K Quarterly results
Docs: "Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress First Patients Treated in Europe with EBVALLOTM Following Transfer of EC Marketing Authorization to Pierre Fabre; Discussions with FDA Progressing ATA188 Phase 2 EMBOLD Study Primary Data Readout On-Track for October 2023 ATA3219 IND Filing Anticipated End of Q2 2023 THOUSAND OAKS, Calif.—May 8, 2023— Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2023, recent business highlights and key upcoming catalysts. “We are entering an important period of potential value-generat..."
03/31/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
02/08/2023 8-K Quarterly results
Docs: "Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress Ebvallo™ EU Launch Activities Led by Pierre Fabre to Commence in Q1 2023 Discussions with FDA Progressing on Potential U.S. BLA for Tab-cel® ATA188 Phase 2 EMBOLD Study Primary Data Readout On-Track for October 2023 Cash Runway Extended into Q2 2024 THOUSAND OAKS, Calif.—February 8, 2022—Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2022, recent business highlights and key upcoming catalysts for 2023. “Following the landmark approval of Eb..."
01/06/2023 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ...
12/20/2022 8-K Quarterly results
12/19/2022 8-K Quarterly results
11/08/2022 8-K Quarterly results
Docs: "Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress EbvalloTM Positioned to be the First Allogeneic T-Cell Therapy Ever Approved Following CHMP Positive Opinion New ATA188 Biomarker Imaging Data Show Less Brain Atrophy and Possible Remyelination in Patients Achieving Confirmed Disability Improvement in Progressive MS Phase 1study of ATA2271 Enrollment Resumed Conference Call and Webcast Today at 1:30 p.m. PST / 4:30 p.m. EST THOUSAND OAKS, Calif.--November 8, 2022-- Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2022, recent business highligh..."
09/28/2022 8-K Quarterly results
09/27/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Second Amended and Restated Bylaws of Atara Biotherapeutics, Inc.",
"Second Amended and Restated Bylaws of Atara Biotherapeutics, Inc."
08/08/2022 8-K Quarterly results
06/24/2022 8-K Quarterly results
05/19/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
04/04/2022 8-K Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits  Interactive Data
Docs: "Asset Purchase Agreement, by and between Atara Biotherapeutics, Inc., FUJIFILM Diosynth Biotechnologies California, Inc., and for certain limited purposes, FUJIFILM Holdings America Corporation",
"Asset Purchase Agreement, by and between Atara Biotherapeutics, Inc., FUJIFILM Diosynth Biotechnologies California, Inc., and for certain limited purposes, FUJIFILM Holdings America Corporation"
02/28/2022 8-K Quarterly results
02/18/2022 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
01/26/2022 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Departure of Directors or Certain ...
Docs: "Atara Biotherapeutics Enters Strategic Manufacturing Partnership with Fujifilm"
01/10/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate Slide Presentation"
11/26/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549",
"Sales Agreement, by and between Atara Biotherapeutics, Inc. and Cowen and Company, LLC",
"Opinion of Sidley Austin LLP"
11/04/2021 8-K Quarterly results
Docs: "Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress Positive Pivotal Phase 3 ALLELE Data Reinforcing the Transformative Potential of Tab-cel®"
10/04/2021 8-K Entry into a Material Definitive Agreement  Interactive Data
08/10/2021 8-K Quarterly results
08/09/2021 8-K Quarterly results
Docs: "Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress Progress with FDA on evaluating tab-cel ® product comparability and new robust Phase 3 ALLELE study data"
06/09/2021 8-K Quarterly results
05/04/2021 8-K Quarterly results
03/01/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
01/04/2021 8-K Quarterly results
12/09/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Underwriting Agreement, by and among Atara Biotherapeutics, Inc., Citigroup Global Markets Inc., Evercore Group L.L.C. and Mizuho Securities USA LLC",
"Form of Pre-Funded Warrant",
"Opinion of Cooley LLP"
12/07/2020 8-K Entry into a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy